Page 1 | Search Results | Blood | American Society of Hematology

1-18 of 18

Sort by

Sort Order Select

Journal Articles

Alternative Lymphodepletion Strategies Lead to Similar Response Rates and Toxicities in Standard-of-Care BCMA-Directed CAR-T Therapy in Relapsed Refractory Multiple Myeloma

Blood (2023) 142 (Supplement 1): 3499.

https://doi.org/10.1182/blood-2023-187565

Published: 2023

Journal Articles

Primary and Secondary Plasma Cell Leukemia Risk Stratification By Circulating Plasma Cells

Andrew Y Li, Farin Kamangar, Noa G. Holtzman, Aaron P. Rapoport, Mehmet H. Kocoglu, Djordje Atanackovic, Zeba N Singh, Sameer Sawhney, Ying S Zou, Ashraf Z. Badros

Blood (2023) 142 (Supplement 1): 6627.

https://doi.org/10.1182/blood-2023-178314

Published: 2023

Journal Articles

Real World Experience with a Zuma -1 Cohort 4 Adopted Approach to CRS and Icans in CAR-T Recipients

Chiranjeevi Sainatham, Olga Goloubeva, Philip Margiotta, Hanan Alharthy, Imari Patel, Ali Bukhari, Jennie Law, Seung Tae Lee, Mehmet H. Kocoglu, Jean A. Yared, Nancy M. Hardy, Maggie Nelson, Joseph P McGuirk, Aaron P. Rapoport, Saurabh Dahiya, Forat Lutfi

Blood (2023) 142 (Supplement 1): 2122.

https://doi.org/10.1182/blood-2023-183002

Published: 2023

Journal Articles

Early Safety Results of P-BCMA-ALLO1, a Fully Allogeneic Chimeric Antigen Receptor T-Cell (CAR-T), in Patients with Relapsed / Refractory Multiple Myeloma (RRMM)

Blood (2023) 142 (Supplement 1): 3479.

https://doi.org/10.1182/blood-2023-182430

Published: 2023

Journal Articles

In Vivo Anti-BCMA CAR T-Cell Expansion Kinetics Correlate with Early IMWG Response in RRMM: A Single Institution Study with Comparative Analysis of Idecabtagene Vicleucel and Ciltacabtagene Autoleucel

Mehmet H. Kocoglu, Aaron P. Rapoport, Tim Luetkens, Etse Gebru, Destiny Omili, Jean A. Yared, Nancy M. Hardy, Soren M Bentzen, Ashraf Z. Badros, Djordje Atanackovic

Blood (2023) 142 (Supplement 1): 1973.

https://doi.org/10.1182/blood-2023-189468

Published: 2023

Journal Articles

Fludarabine Lymphodepletion Exposure Is Associated with Idecabtagene Vicleucel Toxicity in Relapsed and Refractory Multiple Myeloma Patients: Real-World Experience from the US Myeloma Immunotherapy Consortium

Blood (2023) 142 (Supplement 1): 4880.

https://doi.org/10.1182/blood-2023-187440

Published: 2023

Journal Articles

Similar Survival for African American and Caucasian Multiple Myeloma Patients Receiving Auto-SCT

Cameron Dell, BS, Olga Goloubeva, PhD MSc, Aaron P. Rapoport, MD, Mehmet H. Kocoglu, MD, Nancy M. Hardy, MD, Jean Yared, MD, Ning Ma, CRNP, Ashraf Z. Badros, MD

Blood (2017) 130 (Supplement 1): 2177.

https://doi.org/10.1182/blood.V130.Suppl_1.2177.2177

Published: 2017

Journal Articles

Plasma Cell Leukemia (PCL): Clinical Characteristics, Outcomes, and the Impact of Circulating Plasma Cells (CPC) Percentage — A Single Center Experience

Noa G. Holtzman, MD, Olga Goloubeva, PhD MSc, Zeba Singh, MBBS, Sameer Sawhney, MD, Ying Zou, MD PhD, Jean Yared, MD, Nancy M. Hardy, MD, Aaron P. Rapoport, MD, Mehmet H. Kocoglu, MD, Ashraf Z. Badros, MD

Blood (2017) 130 (Supplement 1): 3035.

https://doi.org/10.1182/blood.V130.Suppl_1.3035.3035

Published: 2017

Journal Articles

Pembrolizumab in Combination with Pomalidomide and Dexamethasone for Relapsed/Refractory Multiple Myeloma (RRMM)

Ashraf Z Badros, MD, Elizabeth Hyjek, MD PhD, Ning Ma, Alexander M. Lesokhin, MD, Aaron P. Rapoport, MD, Mehmet H. Kocoglu, MD, Emily Lederer, RN, Sunita Philip, MBBS, Patricia Lesho, Ashlee Johnson, Cameron Dell, Olga Goloubeva, PhD, Zeba Singh, MD

Blood (2016) 128 (22): 490.

https://doi.org/10.1182/blood.V128.22.490.490

Published: 2016

Journal Articles

Niche-Dependent Growth of Malignant and Pre-Neoplastic Plasma Cells in Humanized Mice

Rituparna Das, PhD, Till Strowig, PhD, Rakesh Verma, PhD, Srinivas Koduru, PhD, Anja Hafemann, PhD, Stephanie Hopf, Mehmet H. Kocoglu, MD, Chiara Borsotti, PhD, Lin Zhang, Andrew R Branagan, MD, Elizabeth Eynon, PhD, Markus Manz, MD, Richard Flavell, PhD, Madhav V Dhodapkar, MD

Blood (2015) 126 (23): 120.

https://doi.org/10.1182/blood.V126.23.120.120

Published: 2015

Journal Articles

Humanized Mouse Model of Myeloma Reveals Clinically Occult Genomic Changes in Primary Tumor Cells

Rakesh Verma, PhD, Till Strowig, PhD, Rituparna Das, PhD, Srinivas Koduru, PhD, Anja Hafemann, PhD, Stephanie Hopf, Mehmet H. Kocoglu, MD, Chiara Borsotti, PhD, Lin Zhang, Andrew R Branagan, MD, Elizabeth Eynon, PhD, Markus Manz, MD, Richard Flavell, PhD, Madhav V Dhodapkar, MD

Blood (2015) 126 (23): 22.

https://doi.org/10.1182/blood.V126.23.22.22

Published: 2015

Journal Articles

A Phase II Study of Anti PD-1 Antibody Pembrolizumab, Pomalidomide and Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma (RRMM)

Ashraf Z. Badros, MD, Mehmet H. Kocoglu, MD, Ning Ma, NP, Aaron P. Rapoport, MD, Emily Lederer, RN, Sunita Philip, MBBS, Patricia Lesho, Cameron Dell, Nancy M. Hardy, MD, Jean Yared, MD, Olga Goloubeva, PhD, Zeba Singh, MD

Blood (2015) 126 (23): 506.

https://doi.org/10.1182/blood.V126.23.506.506

Published: 2015

Journal Articles

Racial Differences in Molecular Cytogenetic Abnormalities in Black and White Patients with Multiple Myeloma (MM): A Single-Center Experience

Ying S Zou, MD PhD, Yi Huang, PhD, Zhou Feng, Sin Chan, Shweta Shukla, Ina Lee, MDPhD, Zeba Singh, MD, Mehmet H. Kocoglu, MD, Aaron P. Rapoport, MD, Ning Ma, Nancy M. Hardy, MD, Jean Yared, MD, Maria R Baer, MD, Ashraf Z Badros, MD

Blood (2015) 126 (23): 1767.

https://doi.org/10.1182/blood.V126.23.1767.1767

Published: 2015

Journal Articles

Outcome Comparison of Lymphoma and Myeloma Patients after Autologous Stem Cell Transplantation (ASCT) with Peripheral Blood Stem Cell Mobilization Between Plerixafor (P) Mobilized in Poor Mobilizer Patients and Non-Plerixafor Mobilized Patients

Shahbaz A. Malik, MD, Saul Yanovich, MD, Aaron P. Rapoport, MD, Ashraf Z Badros, MD, Nancy M. Hardy, MD, Mehmet H. Kocoglu, MD, Alison Duffy, Kathleen Ruehle, Jennifer Nishioka, Olga Goloubeva, PhD, Jean Yared, MD

Blood (2015) 126 (23): 5507.

https://doi.org/10.1182/blood.V126.23.5507.5507

Published: 2015

Journal Articles

Enrichment Of Embryonal Stem Cell Signature and Persistent Genomic Complexity In Residual Disease Following Pomalidomide Therapy In Myeloma

Rakesh Verma, Ph.D, Kartik Sehgal, MBBS, Lin Zhang, Mehmet H. Kocoglu, MD, Kavita Dhodapkar, MD, Madhav V. Dhodapkar, MD

Blood (2013) 122 (21): 4200.

https://doi.org/10.1182/blood.V122.21.4200.4200

Published: 2013

Journal Articles

Both Intermittent and Continuous Dosing Regimens Of Pomalidomide Mediate Broad Activation Of Innate and Adaptive Immunity In Relapsed/Refractory Myeloma: Results Of A Phase II Randomized Trial

Kavita Dhodapkar, MD, Lin Zhang, Rakesh Verma, Ph.D, Kartik Sehgal, MBBS, Mehmet H. Kocoglu, MD, Madhav V. Dhodapkar, MD

Blood (2013) 122 (21): 1949.

https://doi.org/10.1182/blood.V122.21.1949.1949

Published: 2013

Journal Articles

Comparison Of Intermittent and Continuous Dosing Regimens Of Pomalidomide In Relapsed/Refractory Myeloma: Results Of A Phase II Randomized Trial

Kartik Sehgal, MBBS, Mehmet H. Kocoglu, MD, Yanhong Deng, Rakesh Verma, Ph.D, Lin Zhang, Dennis L. Cooper, MD, Xiaopan Yao, Kavita Dhodapkar, MD, Madhav V. Dhodapkar, MD

Blood (2013) 122 (21): 3205.

https://doi.org/10.1182/blood.V122.21.3205.3205

Published: 2013

Journal Articles

Development of a Novel in Vivo Model for Human Myeloma Via Humanization of the Bone Marrow Niche

Till Strowig, Anja Hafemann, Stephanie Hopf, Kartik Sehgal, Srinivas Koduru, Mehmet H. Kocoglu, MD, Rituparna Das, Madhav V. Dhodapkar, MD, Richard A. Flavell, PhD

Blood (2012) 120 (21): 325.

https://doi.org/10.1182/blood.V120.21.325.325

Published: 2012

NARROW

Alternative Lymphodepletion Strategies Lead to Similar Response Rates and Toxicities in Standard-of-Care BCMA-Directed CAR-T Therapy in Relapsed Refractory Multiple Myeloma

Primary and Secondary Plasma Cell Leukemia Risk Stratification By Circulating Plasma Cells

Real World Experience with a Zuma -1 Cohort 4 Adopted Approach to CRS and Icans in CAR-T Recipients

Early Safety Results of P-BCMA-ALLO1, a Fully Allogeneic Chimeric Antigen Receptor T-Cell (CAR-T), in Patients with Relapsed / Refractory Multiple Myeloma (RRMM)

In Vivo Anti-BCMA CAR T-Cell Expansion Kinetics Correlate with Early IMWG Response in RRMM: A Single Institution Study with Comparative Analysis of Idecabtagene Vicleucel and Ciltacabtagene Autoleucel

Fludarabine Lymphodepletion Exposure Is Associated with Idecabtagene Vicleucel Toxicity in Relapsed and Refractory Multiple Myeloma Patients: Real-World Experience from the US Myeloma Immunotherapy Consortium

Similar Survival for African American and Caucasian Multiple Myeloma Patients Receiving Auto-SCT

Plasma Cell Leukemia (PCL): Clinical Characteristics, Outcomes, and the Impact of Circulating Plasma Cells (CPC) Percentage — A Single Center Experience

Pembrolizumab in Combination with Pomalidomide and Dexamethasone for Relapsed/Refractory Multiple Myeloma (RRMM)

Niche-Dependent Growth of Malignant and Pre-Neoplastic Plasma Cells in Humanized Mice

Humanized Mouse Model of Myeloma Reveals Clinically Occult Genomic Changes in Primary Tumor Cells

A Phase II Study of Anti PD-1 Antibody Pembrolizumab, Pomalidomide and Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma (RRMM)

Racial Differences in Molecular Cytogenetic Abnormalities in Black and White Patients with Multiple Myeloma (MM): A Single-Center Experience

Outcome Comparison of Lymphoma and Myeloma Patients after Autologous Stem Cell Transplantation (ASCT) with Peripheral Blood Stem Cell Mobilization Between Plerixafor (P) Mobilized in Poor Mobilizer Patients and Non-Plerixafor Mobilized Patients

Enrichment Of Embryonal Stem Cell Signature and Persistent Genomic Complexity In Residual Disease Following Pomalidomide Therapy In Myeloma

Both Intermittent and Continuous Dosing Regimens Of Pomalidomide Mediate Broad Activation Of Innate and Adaptive Immunity In Relapsed/Refractory Myeloma: Results Of A Phase II Randomized Trial

Comparison Of Intermittent and Continuous Dosing Regimens Of Pomalidomide In Relapsed/Refractory Myeloma: Results Of A Phase II Randomized Trial

Development of a Novel in Vivo Model for Human Myeloma Via Humanization of the Bone Marrow Niche

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only